Uninfected to Cervical HPV infection (HPV incidence) |
Age |
|
|
16–19 |
0.0855 |
Barnabas and Garnett, 2004; Schiffman and Kjaer, 2003; Melkert et al, 1993 |
|
20–24 |
0.2500 |
|
|
25–29 |
0.1500 |
|
|
30–34 |
0.0576 |
|
|
35–39 |
0.0333 |
|
|
40–44 |
0.0333 |
|
|
45–49 |
0.0333 |
|
|
50+ |
0.0222 |
|
|
|
|
|
Cervical HPV infection to Uninfected |
Age |
|
|
|
16–29 |
0.7000 |
Myers et al, 2000; Hildesheim et al, 1994; Moscicki et al, 1998; Koutsky et al, 1992; Ho et al, 1998; Molano et al, 2003
|
|
30+ |
0.4130 |
|
|
|
|
|
Cervical HPV infection to CIN 1 or CIN 2 |
0.0959 |
|
Myers et al, 2000; Moscicki et al, 1998
|
Proportion of Cervical HPV infection progressing directly to CIN 2 |
0.1350 |
Myers et al, 2000; Schlecht et al, 2001 |
|
|
|
|
CIN 1 to Cervical HPV infection or Uninfected |
Age |
|
|
|
16–34 |
0.2248 |
Myers et al, 2000; Yokoyama et al, 2003; Syrjanen et al, 1992; de Brux et al, 1983
|
|
35+ |
0.1124 |
|
|
|
|
|
Proportion CIN 1 regressing directly to Uninfected |
0.90 |
Syrjanen et al, 1992 |
|
|
|
|
CIN 1 to CIN 2 |
Age |
|
|
|
16–34 |
0.0297 |
de Brux et al, 1983; Syrjanen et al, 1992; Myers et al, 2000
|
|
35+ |
0.1485 |
|
|
|
|
|
CIN 1 to CIN 3 |
0.0301 |
Yokoyama et al, 2003 |
|
|
|
|
CIN 2 to Cervical HPV infection or Uninfected |
0.1901 |
Yokoyama et al, 2003 |
Proportion CIN 2 regressing directly to Uninfected |
0.90 |
Syrjanen et al, 1992 |
|
|
|
|
CIN 2 to CIN 1 |
0.2430 |
Syrjanen et al, 1992 |
|
|
|
|
CIN2 to CIN 3 |
Age |
|
|
|
16–34 |
0.0389 |
Syrjanen et al, 1992; de Brux et al, 1983; Yokoyama et al, 2003
|
|
35–44 |
0.0797 |
|
|
45+ |
0.1062 |
|
|
|
|
|
CIN 3 to Cervical HPV infection or Uninfected |
Age |
|
|
|
16–44 |
0.0135 |
Syrjanen et al, 1992 |
|
45+ |
0.0100 |
|
Proportion CIN 3 regressing directly to Uninfected |
0.50 |
Syrjanen et al, 1992 |
|
|
|
|
CIN 3 to CIN 1 |
0 |
— |
CIN 3 to CIN 2 |
0.0135 |
— |
|
|
|
|
CIN 3 to Invasive cervical cancer |
0.0099 |
Syrjanen et al, 1992; Ostor, 1993; McIndoe et al, 1984 |
|
|
|
|
Invasive cervical cancer to Death from invasive cervical cancer |
0.025 |
— |
|
|
|
|
Transitions to Death from other cause |
Age |
|
|
|
16–24 |
0.0003 |
Office of National Statistics, 2003a |
|
25–34 |
0.0004 |
|
|
35–44 |
0.0010 |
|
|
45–54 |
0.0026 |
|
|
55–64 |
0.0066 |
|
|
65–74 |
0.0192 |
|